Proteomics is the comprehensive analysis of proteins present in biological systems. It is widely used in protein identification, structural proteomics, post-translational modifications (PTMs), protein qualification, and more. The industry is expanding due to advancements in technology and techniques, increased use of personalized medications, and significant R&D expenditures by major players and research institutions. Major companies such as Thermo Fisher Scientific Inc., Agilent Technologies, Bruker Corporation, and many others have adopted strategic alliances, joint ventures, and acquisitions to promote technological innovation and strengthen their position in the industry.
Various tools and techniques are utilized in proteomics
The study of proteins is an important aspect of biology, as they are the actual functional molecules in cells. Thus, proteomics is also an emerging sector, and relies on various techniques and tools, including mass spectrometry (MS), 2D gel electrophoresis, bioinformatics, and liquid chromatography (LC) to study proteins at length.
2D gel electrophoresis enables researchers to see protein patterns by separating proteins according to their molecular weight and isoelectric point. In addition, mass spectrometry is typically used in combination with liquid chromatography to identify and quantify proteins, as well as to measure the mass-to-charge ratio of peptides. Bioinformatics contributes to analyzing and interpreting proteomic data, further helping to understand protein interactions and pathways with the use of specialized software. Also, innovation in these techniques enables proteomics to advance in sensitivity, scalability, and accessibility, particularly in key applications such as biomarker discovery, personalized medicine, and drug development. For example, improvements in single-cell proteomics are the most recent advancements in mass spectrometry, allowing for accurate and high-throughput measurement of proteins from individual cells. Additional developments include integration of AI and ML algorithms for de novo sequencing, function prediction, and automated data interpretation.
Ongoing developments in applications revolutionizing the sector
According to the Proteomics Market, it finds diverse applications in various fields, focusing on personalization and precision medicines, where protein profiles enable tailored treatments and help identify disease biomarkers. According to AMR, the industry is estimated to rise at a CAGR of 14.2% from 2024 to 2035. Moreover, as precision medicine witnesses a rise in demand, proteomics is likely to play a key role in identifying disease-specific biomarkers, allowing for early diagnosis and targeted therapies. The integration of AI and ML is one of the key factors anticipated to improve data interpretation, advance drug discovery, and enhance clinical outcomes. Proteomics tracks tumor-specific proteins and signaling pathways and can also aid in early detection, prognosis, and therapy monitoring in the field of cancer research. Also, they are widely used in toxicology and drug discovery to find new drug targets and assess how medications impact protein expression. Furthermore, due to the COVID-19 pandemic, the industry has seen an increase in applications that support the study of infectious diseases and vaccine development by clarifying and focusing on host-pathogen interactions and immune responses. Various trends highlight a shift toward more targeted approaches of proteomics in other end uses, including neuroproteomics, spatial proteomics, agriculture, and environmental proteomics.
Innovations in mass spectrometry by Thermo Fisher are redefining proteomics
Recently, Thermo Fisher Scientific has introduced various product advancements in proteomics to enable high sensitivity, throughput, and automation. Its most famous advancement, Orbitrap Eclipse Tribrid mass spectrometry, has undergone several upgrades to enhance faster acquisition speeds and improve single-cell proteomics capabilities. In the latest news, Thermo Fisher Scientific Inc., at the 2025 American Society for Mass Spectrometry (ASMS) conference, announced the launch of the Thermo Scientific Orbitrap Astral Zoom mass spectrometry and Thermo Scientific Orbitrap Excedion Pro mass spectrometry. Both these instruments are developed and designed to advance scientific discovery by enhancing capabilities in proteomics, clinical research, and drug discovery. In addition, Thermo Fisher is actively adopting strategies such as product launches and acquisitions, demonstrating its capabilities to strengthen its market presence and foster innovation in the field. Thermo Fisher’s strategy to launch innovative tools highlights its dedication to offering state-of-the-art instruments utilized in a broad range of applications, including fundamental research, and clinical and pharmaceutical developments. These instruments improve workflows and enable scientific breakthroughs across a range of fields by incorporating cutting-edge technologies.
Conclusion
The proteomics industry is expected to witness highly promising growth in the coming years, driven by rapid technological advancements, high demand for personalized medicine, and increased applications in healthcare, agriculture, and environmental sciences. In addition, the number of point-of-care diagnostics is on the rise, especially in emerging markets, which is anticipated to offer lucrative opportunities for portable and cost-effective proteomics solutions.
Furthermore, due to increased R&D investments and strategic partnerships between biotech, pharmaceutical, and research institutes and academies, the industry is expected to experience growth and innovation during the forecast period.
